Edgar Lomax Co. VA Cuts Stock Holdings in Pfizer Inc. $PFE

Edgar Lomax Co. VA lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 23.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 610,007 shares of the biopharmaceutical company’s stock after selling 182,473 shares during the period. Edgar Lomax Co. VA’s holdings in Pfizer were worth $15,543,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of PFE. Peak Asset Management LLC grew its holdings in shares of Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares in the last quarter. Community Bank & Trust Waco Texas grew its stake in shares of Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after buying an additional 412 shares in the last quarter. Able Wealth Management LLC grew its stake in shares of Pfizer by 2.0% in the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 413 shares in the last quarter. CVA Family Office LLC increased its holdings in shares of Pfizer by 3.3% in the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 413 shares during the last quarter. Finally, Boltwood Capital Management raised its position in shares of Pfizer by 0.7% during the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after buying an additional 420 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.0%

PFE stock opened at $26.63 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a market capitalization of $151.43 billion, a PE ratio of 19.58 and a beta of 0.47. The firm’s 50-day moving average is $26.26 and its 200 day moving average is $25.46. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is presently 126.47%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Federal judge approved a settlement awarding Pfizer $29 million related to the SEC’s 2013 insider‑trading case involving SAC Capital, closing a long‑running legal dispute and delivering a modest one‑time cash gain. Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
• Positive Sentiment: Argus Research upgraded PFE to Buy with a $35 target, highlighting encouraging progress in Pfizer’s GLP‑1 obesity program and its oncology pipeline — a bullish catalyst for longer‑term revenue growth expectations. Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline
• Positive Sentiment: Investor writeups note portfolio renewal progress and attractive dividend yield for patient investors, framing Pfizer as a value/dividend play while its pipeline rebuild continues. Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Some outlets note the stock is down modestly since the last earnings release and are asking whether it can rebound — a monitoring signal rather than fresh news. Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
• Neutral Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a partnership update that points to operational/automation improvements but is unlikely to move near‑term revenues. Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Neutral Sentiment: Valuation pieces note divergence between long‑term return expectations and DCF views, signaling mixed investor opinions on fair value and outlook. A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge
• Negative Sentiment: Analysis highlights structural growth challenges — falling COVID revenues, upcoming patent expirations and pricing/IRA headwinds — that could pressure sales and margins if new launches don’t scale. Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
• Negative Sentiment: Opinion pieces warn of “obesity hype” and potential vaccine policy shocks that could create volatility around expectations for new GLP‑1 products and vaccine revenues. Pfizer: Obesity Hype And Vaccine Policy Shocks

Analysts Set New Price Targets

Several research analysts recently commented on PFE shares. Citigroup began coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. Scotiabank initiated coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Bank of America reduced their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Finally, Morgan Stanley dropped their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.05.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.